Takeda Gives Sun Pharma, Cipla Rights to Commercialise Gastro Drug in India

[ad_1] Gastroesophageal reflux disease (GERD) affects 5% to 28.5% of India’s population. Takeda has granted both drugmakers non-exclusive patent licensing rights for the drug Japan’s Takeda Pharmaceutical gave India’s Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country. The drug, which is sold in the form of tablets under the…

Read More